Market access is now too complex for historical analogues — and AI is the only tool that can model what comes next.
Jen Norton
Advertisement
Jen leads EVERSANA’s market access, pricing, and reimbursement strategies, helping life sciences innovators overcome barriers to drug access and affordability. With more than two decades of leadership in the pharmaceutical market access landscape, Jen brings deep therapeutic expertise across specialty products, biosimilars, oncology, and rare diseases.
Articles by Jen Norton
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novartis & BoomRay Enter Global License Agreement for Preclinical Radioligand Asset
2
Nine European Drugmakers Warn the Continent Risks Losing the Pharma Investment Race: Report
3
How Recent FDA Actions Impact Sponsors
4
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
5